Abiopharma

🔍 LUSTIG MATTHEW J (Director)

Company: BXP, Inc. (BXP)

Report Date: 2026-03-31

Detailed Transactions and Holdings:

• Acquired 578 shares of Phantom Stock Units (Derivative)
  Date: 2026-03-31 | Code: A | equity_swap_involved: 0 | shares_owned_after: 20,826.42 | transaction_form_type: 4 | Footnotes: F1, F2, F2, F3

Footnotes:

• F1: The Phantom Stock Units convert to BXP, Inc. ("BXP") common stock on a 1-for-1 basis.
• F2: The Phantom Stock Units are awarded under BXP's 2021 Stock Incentive Plan to non-employee directors who elected to receive Phantom Stock Units in lieu of director cash compensation fees. The Phantom Stock Units are to be settled in shares of BXP common stock (except that fractional units, if any, will be settled in cash) in a lump sum or in ten annual installments, at the reporting person's election, following the reporting person's retirement from the BXP Board of Directors. In addition, non-employee directors who elect a deferred payout following their retirement may make one or more elections to reallocate all or a portion (but only in 25% increments) of their notional investment from BXP common stock to a deemed investment in one or more measurement funds. These elections may only be made after the director's service on the BXP Board of Directors ends. Amounts notionally invested in measurement funds will be settled in cash instead of BXP common stock.
• F3: Includes 215.70 Phantom Stock Units received pursuant to dividend equivalent rights which were credited to the Reporting Person on January 29, 2026.